Institutional Ownership
Sab Biotherapeutics Inc
CUSIP 78397T202COM NEWSABSQ1 2026
13D / 13G Filings
12
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
10.0%
Max % of class reported
Institutional Holders
72
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
12 filings · latest Mar 11, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 11, 2026 | Ra Capital Management, L.P. | 13D/A | 9.9% | — | SEC |
| 2 | Feb 17, 2026 | Rtw Investments, LP | 13G/A | 3.2% | 1.59M | SEC |
| 3 | Feb 17, 2026 | Biotechnology Value Fund L P | 13G/A | 9.1% | 4.76M | SEC |
| 4 | Jan 22, 2026 | Perceptive Advisors LLC | 13G | 7.3% | 3.47M | SEC |
| 5 | Nov 14, 2025 | Biotechnology Value Fund L P | 13G/A | 10.0% | 5.17M | SEC |
| 6 | Nov 14, 2025 | Woodline Partners LP | 13G | 9.9% | 7.13M | SEC |
| 7 | Oct 3, 2025 | Commodore Capital LP | 13G | 9.9% | 4.52M | SEC |
| 8 | Oct 3, 2025 | Ra Capital Management, L.P. | 13D | 9.9% | — | SEC |
| 9 | Oct 3, 2025 | Vivo Opportunity Fund Holdings, L.P. | 13G | 10.0% | 25.93M | SEC |
| 10 | Feb 14, 2025 | Rtw Investments, LP | 13G/A | 10.0% | 1.02M | SEC |
2 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Sab Biotherapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Vivo Capital, LLC | 11.42M | $43.74M |
| 2 | Caligan Partners LP | 7.97M | $30.51M |
| 3 | Perceptive Advisors LLC | 6.43M | $24.63M |
| 4 | Ra Capital Management, L.P. | 4.40M | $16.86M |
| 5 | Commodore Capital LP | 4.40M | $16.86M |
| 6 | Balyasny Asset Management L.P. | 3.76M | $14.40M |
| 7 | Adage Capital Partners Gp, L.L.C. | 3.41M | $13.04M |
| 8 | Millennium Management LLC | 3.03M | $11.62M |
| 9 | Woodline Partners LP | 2.85M | $10.92M |
| 10 | Spruce Street Capital LP | 2.20M | $8.42M |